Phase 2
Regeneron indicated that because of disappointing results for two Phase II trials, it was ending its development of angiopoietin2 antibody nesvacumab as an addition to Eylea.
Researchers are making great headway against cancer, even though it’s currently still the second-leading cause of death in the U.S.
PellePharm is aiming to launch Phase III trials of the topical hedgehog inhibitor in early 2018.
Two months after positive preliminary data showed sitravatinib in combination with Opdivo demonstrated some efficacy in treating patients with NSCLC, Mirati said it will reprioritize its R&D to focus.
Five Prime stock took a beating after it unintentionally released Phase Ia/Ib clinical trial of its CSF-1R antibody cabiralizumab with BMS’ Opdivo (nivolumab).
Novartis announced they have expanded their collaboration with the Banner Alzheimer’s Institute to launch a new clinical trial in ALZ’s.
For most biopharma sponsors, the crux of their challenge is how to identify an adequate number of evaluable patients to sufficiently power their late phase clinical research.
Bluebird is making forays into the CAR-T immuno-oncology market, although it has yet to bring a product to market.
BioMarin announced that the FDA granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation.
Aldeyra Therapeutics presented novel data at the American Society of Human Genetics 2017 Annual Meeting demonstrating that ADX-102 reduced levels of gamma-hydroxybutyrate (GHB) and gamma-aminobutyrate (GABA) in a knockout mouse model of Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency.
PRESS RELEASES